pI: 8.0822 |
Length (AA): 347 |
MW (Da): 41207 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
17 | 339 | 1fkm (A) | 249 | 629 | 43.00 | 0 | 1 | 1.69 | -2.66 |
17 | 340 | 1fkm (A) | 249 | 630 | 42.00 | 0 | 1 | 1.57942 | -1.63 |
21 | 339 | 2qfz (A) | 196 | 508 | 46.00 | 0 | 1 | 1.53961 | -1.38 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | intra-erythrocytic - 32 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, gametocyte, early schizont. | Otto TD PlasmoDB |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 24 hs, early trophozoite, late schizont, late trophozoite, Female Gametocyte. | Otto TD PlasmoDB Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | intra-erythrocytic - 8 hs, late ring, Oocyst, Male Gametocyte. | Otto TD PlasmoDB Zanghi G Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | intra-erythrocytic - 16 hs, Ring, Sporozoite. | Otto TD Zanghi G |
PlasmoDB | Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Ortholog group members (OG5_127685)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G30710 | RabGAP/TBC domain-containing protein |
Babesia bovis | BBOV_II002460 | TBC domain containing protein |
Brugia malayi | Bm1_37555 | TBC domain containing protein |
Candida albicans | CaO19.11292 | Gtpase activating protein for Ypt1p |
Candida albicans | CaO19.3811 | Gtpase activating protein for Ypt1p |
Caenorhabditis elegans | CELE_F32B6.8 | Protein TBC-3, isoform B |
Cryptosporidium hominis | Chro.30295 | TBC domain |
Cryptosporidium parvum | cgd3_2560 | TBC1 domain containing protein |
Dictyostelium discoideum | DDB_G0269982 | hypothetical protein |
Drosophila melanogaster | Dmel_CG5745 | CG5745 gene product from transcript CG5745-RA |
Echinococcus granulosus | EgrG_001054300 | TBC1 domain family 2B |
Entamoeba histolytica | EHI_196990 | Rab GTPase activating protein, putative |
Echinococcus multilocularis | EmuJ_001054300 | TBC1 domain family 2B |
Homo sapiens | ENSG00000054611 | TBC1 domain family, member 22A |
Homo sapiens | ENSG00000065491 | TBC1 domain family, member 22B |
Leishmania braziliensis | LbrM.30.1470 | GTPase activating protein, putative |
Leishmania donovani | LdBPK_301410.1 | GTPase activating protein, putative |
Leishmania infantum | LinJ.30.1410 | GTPase activating protein, putative |
Leishmania major | LmjF.30.1350 | GTPase activating protein, putative |
Leishmania mexicana | LmxM.29.1350 | GTPase activating protein, putative |
Loa Loa (eye worm) | LOAG_05272 | TBC domain-containing protein |
Mus musculus | ENSMUSG00000042203 | TBC1 domain family, member 22B |
Mus musculus | ENSMUSG00000051864 | TBC1 domain family, member 22a |
Neospora caninum | NCLIV_014640 | TBC domain-containing protein, putative |
Oryza sativa | 4347577 | Os09g0515800 |
Plasmodium berghei | PBANKA_1361300 | TBC domain protein, putative |
Plasmodium falciparum | PF3D7_1348500 | TBC domain protein, putative |
Plasmodium knowlesi | PKNH_1252400 | TBC domain protein, putative |
Plasmodium vivax | PVX_083320 | TBC domain protein, putative |
Plasmodium yoelii | PY05115 | TBC domain, putative |
Saccharomyces cerevisiae | YOR070C | Gyp1p |
Schistosoma japonicum | Sjp_0216130 | TBC1 domain family member 22B, putative |
Schistosoma mansoni | Smp_022130 | hypothetical protein |
Schmidtea mediterranea | mk4.008868.00 | |
Schmidtea mediterranea | mk4.011578.00 | |
Schmidtea mediterranea | mk4.009193.02 | |
Trypanosoma brucei gambiense | Tbg972.6.2600 | GTPase activating protein, conserved, putative |
Trypanosoma brucei | Tb927.6.2830 | GTPase activating protein, conserved |
Trypanosoma congolense | TcIL3000_0_57880 | GTPase activating protein, conserved |
Trypanosoma cruzi | TcCLB.511753.80 | GTPase activating protein, putative |
Trypanosoma cruzi | TcCLB.511501.50 | GTPase activating protein, putative |
Toxoplasma gondii | TGME49_285730 | TBC domain containing protein |
Theileria parva | TP04_0374 | TBC domain protein, putative |
Trichomonas vaginalis | TVAG_235350 | conserved hypothetical protein |
Trichomonas vaginalis | TVAG_329290 | conserved hypothetical protein |
Trichomonas vaginalis | TVAG_483540 | conserved hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.6.2830 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.2830 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.2830 | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.6.2830 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_285730 | Toxoplasma gondii | Essentiality uncertain | sidik |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.2